

05 October 2015

'RESEARCH NEVER STOPS'

info@evotec.com | www.evotec.com

For further information,
please contact

Gabriele Hansen
*VP, Corporate Communications &
Investor Relations*
+49.(0)40.560 81-255
+49.(0)40.560 81-333 Fax
gabriele.hansen@evotec.com

Evotec AG
Manfred Eigen Campus
Essener Bogen 7
22419 Hamburg (Germany)

Evotec awarded multi-year contract to manage National Cancer Institute Chemical Biology Consortium Screening Libraries Center

Hamburg, Germany – 05 October 2015: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced it has entered into a multi-year compound management agreement with the U.S. National Cancer Institute ("NCI"), Department of Health and Human Services. Under the terms of the agreement, Evotec will provide compound management services to the NCI Chemical Biology Consortium ("CBC") for a period of five years with a total estimated value of up to € 4.5 m (\$ 4.9 m).

The NCI Chemical Biology Consortium contract will continue to provide to acquire, store, maintain and distribute the current library collection. This repository will form part of the CBC's drug discovery and development platform for new oncology therapeutics being researched by a consortium of primarily academic and non-profit institutions.

Dr Mario Polywka, Chief Operating Officer of Evotec, commented: "We are pleased the NCI has elected to award Evotec this important contract to support the Chemical Biology Consortium, an important initiative in the discovery of new cancer treatments."

ABOUT THE NCI CHEMICAL BIOLOGY CONSORTIUM (CBC)

The NCI Chemical Biology Consortium ("CBC") was established in 2009 to facilitate the discovery and development of new agents to treat cancer. The Consortium brings together chemical biologists and molecular oncologists from government, industry and academia to address unmet needs in therapeutic oncology. Through the CBC and the interactions among the various participants, the NCI's drug discovery and development pipeline now spans from target identification through proof-of-concept clinical trials. The project is funded in whole with U.S. Federal funds from the National Institutes of Health, Department of Health and Human Services, under contract HHSN261201500010I with Evotec (US), Inc.

ABOUT EVOTEC AG

Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide providing the highest

quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic. The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, pain, metabolic diseases as well as oncology, inflammation and infectious diseases. Evotec has long-term discovery alliances with partners including Bayer, Boehringer Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals, MedImmune/AstraZeneca, Roche and UCB. In addition, the Company has existing development partnerships and product candidates both in clinical and pre-clinical development. These include partnerships with Boehringer Ingelheim and MedImmune in the field of diabetes, with Janssen Pharmaceuticals in the field of depression and with Roche in the field of Alzheimer's disease. For additional information please go to www.evotec.com.

FORWARD LOOKING STATEMENTS — *Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.*